Cipla Reports Robust Q1FY26 Results: Consolidated Net Profit Rises to ₹1,291.61 Cr, Margins Expand

Mumbai, July 25 (IST) – Cipla Ltd (NSE: CIPLA) delivered credible unaudited financial results for the quarter ending on June 30, 2025, with positive trends across its various geographies and profitability metrics.

The pharmaceutical company reported a 13.3 percent year-over-year increase in consolidated net profit after tax, driven by an improved product mix and effective cost control measures. In FY25, the North American market represented 28.7 percent of the company’s revenue.

As of July 25, 2025, at 3:00 pm, Cipla Ltd. is trading at ₹1532.10, representing a 2.97% increase. It has traded between ₹1,485.00 and ₹1,553.70, with the last open being ₹1,487.90. While its previous closing price was ₹1,487.90, and it currently has a slight positive momentum, the intraday movement appears to follow a sideways trend.

Consolidated Financial Highlights (₹ in crore)

The company delivered strong growth in Q1 FY26, reporting revenue from operations of ₹6,957.47 crore, representing a 3.9% year-over-year increase and a 3.4% quarter-over-quarter rise. Total income was ₹7,216.03 crore while the net profit was ₹1,291.61 crore, representing a year-on-year increase of 9.9% and a quarter-on-quarter increase of 6.4%. Profit before tax increased significantly quarter-on-quarter by 17.6%. Basic EPS was ₹15.13, which was flat sequentially but up 3.8% year-on-year.

Segment Performance

Pharmaceuticals, Cipla’s core segment, delivered strong operating leverage with Q1FY26 segment revenue at ₹6,579.42 crore, up 3% YoY. The New Ventures vertical, which includes emerging businesses and innovation-led products, jumped 25% YoY to ₹443.70 crore, reflecting Cipla’s growing footprint in next-gen healthcare initiatives.

In Q1 FY26, total segment revenues increased by 4.1% year over year to ₹7,023.12 crore. The Pharmaceuticals segment experienced 3.0% growth to ₹6,579.42 crore, while the New Ventures segment experienced exceptionally strong growth, up 25.3% to ₹443.70 crore compared to the previous year. The New Ventures increased by ₹137.20 crore compared to last year, which describes strong strides in our emerging businesses.

The segment profit for pharmaceuticals stood at ₹1,727.22 crore while New Ventures delivered ₹56.76 crore, reversing losses reported in the corresponding period last year.

Standalone Financial Highlights

On a standalone basis, Cipla reported a net profit of ₹1,303.13 crore, up 23.4% YoY, with revenues from operations reaching ₹5,046.17 crore. Robust domestic formulations and higher other operating revenues drove the growth.

Regulatory & Legal Update

The company continues to defend against long-standing overcharge claims by the National Pharmaceutical Pricing Authority (NPPA). As of June 2025, Cipla voluntarily deposited ₹27.07 crore, taking total deposits to ₹202.15 crore (against total disputed demand of ₹2,011 crore). However, it has not made any accounting provisions, citing favourable legal advice and pending Supreme Court adjudication.

Management Commentary

Umang Vohra, Managing Director and Global CEO, said: “Our first quarter performance reflects our continued focus on strategic execution, margin expansion, and product innovation. The India and US businesses remain strong, and our differentiated pipeline is translating into sustainable growth.”

Outlook

Cipla aims to strengthen its position in chronic therapies, digital health, and complex generics across regulated markets. New product launches in the respiratory and specialty segments are expected to drive momentum.

REF:https://nsearchives.nseindia.com/corporate/CIPLA_25072025131531_Boardmeetingoutcome25072025FRSigned.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations